Participated · Seed · Aug 2025

Axelyf develops next-generation lipid nanoparticle (LNP) delivery systems to improve RNA therapeutic delivery, combining novel ionizable lipids, advanced surface chemistry and AI-informed design. Its AXL technology integrates assets acquired from 76Bio with Axelyf’s proprietary IP and four distinct ionizable lipid series designed for potency, biodegradability and extrahepatic delivery. The company also built ANNA™, a machine-learning model for lipid optimization, and published a white paper showing ANNA outperformed current AI approaches for predicting LNP performance. Axelyf plans to use the new funding to advance development of its proprietary AXL technology and CMC capabilities. In partner studies AXL lipids demonstrated superior in vivo gene editing potency versus the LP-01 benchmark, higher mouse gene editing efficiency at lower doses without signs of liver toxicity, and high potency for gene insertion with reduced immune stimulation. Its lead investigational candidate, AXL-003, targets an undisclosed autoimmune condition using liver-directed delivery; the company maintains an R&D subsidiary, Axelyf ehf, in Iceland.

Participated · Series C · May 2021

Oculis is a helvetico-Icelandic biopharmaceutical company focused on creating innovative treatments for eye and neurological disorders. The firm is legally based in Zug with its operational headquarters in Lausanne. Its pipeline of ophthalmic therapies has attracted strong investor interest, reflected in two capital increases exceeding $100 million within a year. Management states that the newly secured funds will accelerate the clinical development of its drug candidates. The company positions itself as a leader in addressing unmet medical needs in ophthalmology through novel therapeutic approaches. Financially, Oculis has now raised at least $220 million across its last two rounds, underscoring sustained investor confidence. No revenue or user metrics were disclosed in the available article excerpt.